- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03153358
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
May 13, 2017 updated by: Juan LI, MD, Sichuan Cancer Hospital and Research Institute
Icotinib Combined With Stereotactic Body Radiation Therapy (SBRT) for Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Many patients with oncogene-driven non-small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression.
For multiple metastases in patients with advanced NSCLC, increased local treatment may benefit to prolong patient survival.
This study investigated the benefits of icotinib limited systemic disease progression and continuation of Stereotactic Body Radiation Therapy,in patients with metastatic EGFR-mutant NSCLC.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Lung cancer is the leading cause of cancer morbidity and mortality worldwide.
The majority of lung cancer is nonsquamous NSCLC.
EGFR tyrosine kinase inhibitors (EGFR-TKI) is a effective first-line treatment for EGFR mutations non-squamous NSCLC treatment.Icotinib is the first EGFR-TKI,and have been proved efficiently in the treatment of lung cancer, and SBRT become a main therapy for the primary lesion,Accordingly, we have come to a scientific hypothesis that icotinib combination with SBRT might be a better treatment strategy for stageIV non-squamous NSCLC patients with EGFR mutation.
It can improve the PFS of stage ⅢB/Ⅳ non-squamous NSCLC patients with EGFR mutation .
The primary endpoint is disease-free time to progression (PFS).
The secondary study endpoint is objective response rate (ORR), disease control rate (DCR),overall survival(OS) safety and quality of life (QOL).
Through this study lay the foundation for further exploration of the non-squamous NSCLC first-line treatment in patients with EGFR mutation strategy.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR mutation.
- Stage disease according to the 7th Edition of the American Joint Committee on Cancer staging system
- Not received radiotherapy, chemotherapy or other biological treatment
- Measureable disease
- Life expectancy of>=12 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- Absolute neutrophil count (ANC)>=2,500/mm^3
- Hemoglobin>=9.0 g/dL
- Total bilirubin<=1.5 x upper limit of normal(ULN)
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine transferase [ALT])<=2.5 x ULN in patients without liver or bone metastases; <5 x ULN in patients with liver or bone metastases
- Cockcroft-Gault calculated creatinine clearance of>=45 ml/min or creatinine<=1.5 x ULN
- Prothrombin time (PT)<=1.5 x ULN
- Partial thromboplastin time (PTT)<=ULN
- Negative pregnancy test done<=7 days prior to randomization, for women of childbearing potential only
- Provide informed written consent
- Willing to return to Sichuan cancer hospital for follow-up
- Willing to provide tissue and blood samples for correlative research purposes
Exclusion Criteria:
- Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component
- Known allergic to EGFR TKI any ingredients
- Prior chemotherapy or treatment for metastatic non-small cell lung cancer
- Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive, per MD discretion
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- Other active malignancy<=3 years prior to randomization;
- Ongoing or active infection, symptomatic congestive heart failure , cardiac arrhythmia, psychiatric illness/social situations, or any other medical condition that would limit compliance with study requirements
- History of bleeding diathesis or coagulopathy
- Inadequately controlled hypertension (systolic blood pressure of>150 mmHg or diastolic pressure>100 mmHg on anti-hypertensive medications)
- Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury <=28 days or core biopsy <=7 days prior to randomization
- Pregnancy or breast-feeding women
- Other situation which researchers think that doesn't fit into the group
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: icotinib+SBRT
icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
|
icotinib 125 milligram three times a day
Other Names:
given radiation for the primary lesion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression free survival
Time Frame: four weeks
|
the time to disease to progression according the RESCIT
|
four weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
object responsible rate
Time Frame: four weeks
|
the proportion the patients have receives the complete remission and partial remission
|
four weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 2, 2017
Primary Completion (Anticipated)
November 2, 2017
Study Completion (Anticipated)
May 2, 2019
Study Registration Dates
First Submitted
May 7, 2017
First Submitted That Met QC Criteria
May 11, 2017
First Posted (Actual)
May 15, 2017
Study Record Updates
Last Update Posted (Actual)
May 16, 2017
Last Update Submitted That Met QC Criteria
May 13, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EK2017001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer Stage IV
-
Jerome Canady, M.D.Active, not recruitingStage IV Lung Cancer | Stage IV Bladder Cancer | Stage IV Pancreatic Cancer | Recurrent Malignant Solid Neoplasm | Stage IV Breast Cancer | Stage IV Renal Cell Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Stage IV Non-small Cell Lung Cancer | Stage... and other conditionsUnited States
-
Vestre Viken Hospital TrustOdense University Hospital; Karolinska University Hospital; Oslo University Hospital and other collaboratorsRecruitingCancer | Lung Cancer | NSCLC Stage IV | Mutation | NSCLC, Stage III | Lung Cancer Stage IV | Cancer, LungNorway
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Asan Medical... and other collaboratorsCompletedStage IV Lung Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Pediatric Brain Tumor | Stage IV Colon Cancer | Stage IV Gastric Cancer | Stage IV Liver Cancer | Malignant Hematologic Neoplasm | Pediatric Solid Tumor | Pediatric Lymphoma | Biliary Cancer Metastatic | Pediatric LeukemiaKorea, Republic of
-
Holy Cross Hospital, MarylandWithdrawn
-
Washington University School of MedicineWashington University Department of Psychological and Brain SciencesTerminatedStage III Gynecologic Cancer | Stage IV Gynecologic CancerUnited States
-
Biomea Fusion Inc.RecruitingColorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditionsUnited States, Korea, Republic of
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedStage IV Lung Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Malignant Female Reproductive System Neoplasm | Stage III... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Not yet recruitingStage IV Lung Cancer | Stage III Lung Cancer | Stage II Lung Cancer
-
Maastricht Radiation OncologyAmsterdam UMC, location VUmcCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Breast CarcinomaUnited States
Clinical Trials on Icotinib
-
Anhui Medical UniversityUnknown
-
Betta Pharmaceuticals Co., Ltd.RecruitingNon-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive MutationChina
-
Li PengBetta Pharmaceuticals Co., Ltd.CompletedNeurofibromatosis Type 2 | Vestibular SchwannomaChina
-
Betta Pharmaceuticals Co., Ltd.UnknownNon-small Cell Lung CancerChina
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdCompleted
-
Zhejiang Cancer HospitalUnknownNon-small Cell Lung Cancer | Brain MetastasesChina
-
Betta Pharmaceuticals Co., Ltd.Unknown
-
Cancer Institute and Hospital, Chinese Academy...UnknownNon-small Cell Lung CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingNon Small Cell Lung CancerChina
-
Betta Pharmaceuticals Co., Ltd.RecruitingEGF-R Positive Non-Small Cell Lung CancerChina